Jade Biosciences
JBIO
78 hedge funds and large institutions have $79.9M invested in Jade Biosciences in 2024 Q4 according to their latest regulatory filings, with 26 funds opening new positions, 24 increasing their positions, 13 reducing their positions, and 20 closing their positions.
261% more call options, than puts
Call options by funds: $2.75M | Put options by funds: $761K
85% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 13
38% more capital invested
Capital invested by funds: $57.8M → $79.9M (+$22.2M)
30% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 20
8% more funds holding
Funds holding: 72 → 78 (+6)
0.25% more ownership
Funds ownership: 2.74% → 2.98% (+0.25%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
B
Braidwell
Stamford,
Connecticut
|
+$3.55M |
| 2 |
LGM
Logos Global Management
San Francisco,
California
|
+$3.45M |
| 3 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
+$2.01M |
| 4 |
JFG
Jefferies Financial Group
New York
|
+$1.48M |
| 5 |
Blackstone Inc
New York
|
+$1.23M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$2.95M |
| 2 |
BBA
Baker Bros. Advisors
New York
|
-$1.31M |
| 3 |
EP
Eversept Partners
New York
|
-$1.01M |
| 4 |
OCA
Octagon Capital Advisors
New York
|
-$973K |
| 5 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$920K |
JBIO Hedge Fund Activity: Q4 2024 in Review
78 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Jade Biosciences (JBIO) for Q4 2024, worth a combined $79.9M — up 38% from $57.8M a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new JBIO positions and 20 closed out — a net gain of 6 holders — while 24 added to existing stakes and 13 trimmed.
The largest buyer was Braidwell, opening a new position worth an estimated $3.55M. The largest seller was Deerfield Management, exiting entirely with an estimated $2.95M sold.
- 78 institutional investors held Jade Biosciences (JBIO) as of Q4 2024, up from 72 in Q3 2024.
- Funds reported $79.9M of Jade Biosciences stock for Q4 2024, up 38% quarter-over-quarter.
- 26 funds opened new Jade Biosciences positions in Q4 2024 and 20 closed out, a net change of +6 holders.
- The largest Jade Biosciences buyer in Q4 2024 was Braidwell, an estimated $3.55M added.
- The largest Jade Biosciences seller in Q4 2024 was Deerfield Management, an estimated $2.95M sold.
Based on aggregated 13F filings for Q4 2024.